Citing financial issues, Uroplasty puts CFO on leave, delays filing with SEC

Friday, June 14, 2013

At medical tech firm Uroplasty Inc., things are going from bad to worse. Uroplasty’s troubles come at a bad time, said Jack Militello, Ph.D., management professor and director of the Health Care and Executive UST MBA programs, in the Star Tribune.

Militello said that’s because even the appearance of ethical lapses damages a company’s reputation with investors, making it harder for a firm such as Uroplasty to deal with the medical device pricing pressures that lie just ahead.

But there are also reasons to believe management can succeed, Militello said.

Originally published: 06/14/2013, Star Tribune